Mike Doustdar, new CEO of Ozempic maker, Novo Nordisk discusses his strategy for the future of the company
5/11 2025 21:45 ProInvestorNEWS 3
129449 Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
Det gjorde han faktisk udmaerket.
Interessant svar vedroerende M&A.
1:00
- So should we expect more M&A then?
- You should expect that we actually will not stop. We will not be satisfied, until we have all the capabilities and the assets that are needed to address hundreds of millions of people that are right now suffering from diabetes and/or obesity.
Her sammendrag fra Google Gemini 2.5 Pro:
[00:00:06] Is the company's recent M&A activity a reflection of a new, more aggressive Novo Nordisk?
Answer: The CEO explains that his first move was to refocus the company on diabetes and obesity, an area with a massive "incredibly large unmet need". The strategy is to "build and buy" all necessary assets to accelerate their pipeline and address this need.
[00:00:54] So should we expect more M&A?
Answer: Yes. The CEO states they "will not stop" until they have all the assets needed to treat the "hundreds of millions of people" suffering from diabetes and obesity.
[00:01:16] Is this M&A spree a reflection of a lack of confidence in your own pipeline?
Answer: "Absolutely not". He is "very proud" of their internal pipeline but acknowledges that other companies have assets that are "complementary to what we do".
[00:01:45] Does this focus mean you are moving away from other areas, like cell and gene therapies?
Answer: "It is partially the case". The focus is patient-centric: they get excited if a patient suffers from obesity or diabetes. While their drugs might help related conditions (like liver, kidney, or heart disease), they will not acquire an asset for a condition like kidney disease unless it is also related to diabetes or obesity.
[00:02:52] How much can you improve demand in the US with lower prices and direct-to-consumer access?
Answer: He calls it a "long-term game" and a "marathon". He highlights the "very long runway," noting that of 100 million Americans with obesity, only 3-4 million are currently being treated. Success requires both the right assets and the right "affordability."
[00:03:46] How will lowering prices affect your bottom line and R&D firepower?
Answer: He notes that if you halve the price, you must double the volume. The "good news" is that in their industry, there is "so much volume to untap". A strong pipeline gives them hope for "sustainable leadership."
[00:04:25] Will you announce more direct-to-consumer deals (like with CVS and Costco)?
Answer: "Absolutely. Absolutely". He calls partnerships a "cornerstone" of their strategy to "increase the expansion of the market".
[00:04:58] If US prices go down, will prices increase elsewhere in the world to compensate?
Answer: He states that "price does go down everywhere in the world" as volume increases. However, as long as the company continues to innovate, they will "be able to get value for your innovation".
[00:05:34] How much of a game-changer can the new obesity pill be?
Answer: "A very big one". He says it's the first pill with efficacy "on par with the injectable," so patients won't have to choose between convenience and efficacy. He is also excited it will be the first GLP-1 product "made in US by Americans for Americans".
[00:06:52] What other areas are you looking at for potential impact?
Answer: Alzheimer's. He says it's an area with "huge unmet need" and that if their research proves to have an impact, "this is a gamecher," though he cautions it remains a "high-risk area".
[00:07:24] Where are you in the big restructuring plan?
Answer: It is "almost 95 95% complete" and was done at "record speed" to prevent the company from becoming "paralyzed". The restructuring was necessary to "readjusting our cost base" in the face of "competitive headwind" without sacrificing future investments.
[00:08:56] How difficult is it to have a very powerful chair just behind you?
Answer: He says his job is to set and execute the strategy. He states that the current and incoming board chairs are "all behind my appointment" and the new strategy, which gives him "a huge amount of excitement".
[00:10:27] What is the impact of the Trump administration and tariffs on European pharma?
Answer: He says that since Novo Nordisk exports more from the US than it imports, tariffs are "less of an issue" for them than for peers. He emphasizes they have "very big investments in Europe" as well and "simply try to be where we are operating".
[00:11:31] What is your priority now for Novo Nordisk?
Answer: First, "providing access to our medications" for those with unmet needs. Second, to "go deep into building our pipeline," both internally and through acquisitions, while running a good "sales to to cost ratio".
[00:12:19] What do you say to critics concerned about making anti-obesity drugs widely available?
Answer: He says if you talk to patients who have suffered their whole lives, you'd conclude "it's irresponsible for you not to make that available".
[00:12:44] What about making the drug accessible to people who don't need it?
Answer: He responds that their job is to "focus on those who need it," which is indicated by their drug labels and their entire approach.
Interessant svar vedroerende M&A.
1:00
- So should we expect more M&A then?
- You should expect that we actually will not stop. We will not be satisfied, until we have all the capabilities and the assets that are needed to address hundreds of millions of people that are right now suffering from diabetes and/or obesity.
Her sammendrag fra Google Gemini 2.5 Pro:
[00:00:06] Is the company's recent M&A activity a reflection of a new, more aggressive Novo Nordisk?
Answer: The CEO explains that his first move was to refocus the company on diabetes and obesity, an area with a massive "incredibly large unmet need". The strategy is to "build and buy" all necessary assets to accelerate their pipeline and address this need.
[00:00:54] So should we expect more M&A?
Answer: Yes. The CEO states they "will not stop" until they have all the assets needed to treat the "hundreds of millions of people" suffering from diabetes and obesity.
[00:01:16] Is this M&A spree a reflection of a lack of confidence in your own pipeline?
Answer: "Absolutely not". He is "very proud" of their internal pipeline but acknowledges that other companies have assets that are "complementary to what we do".
[00:01:45] Does this focus mean you are moving away from other areas, like cell and gene therapies?
Answer: "It is partially the case". The focus is patient-centric: they get excited if a patient suffers from obesity or diabetes. While their drugs might help related conditions (like liver, kidney, or heart disease), they will not acquire an asset for a condition like kidney disease unless it is also related to diabetes or obesity.
[00:02:52] How much can you improve demand in the US with lower prices and direct-to-consumer access?
Answer: He calls it a "long-term game" and a "marathon". He highlights the "very long runway," noting that of 100 million Americans with obesity, only 3-4 million are currently being treated. Success requires both the right assets and the right "affordability."
[00:03:46] How will lowering prices affect your bottom line and R&D firepower?
Answer: He notes that if you halve the price, you must double the volume. The "good news" is that in their industry, there is "so much volume to untap". A strong pipeline gives them hope for "sustainable leadership."
[00:04:25] Will you announce more direct-to-consumer deals (like with CVS and Costco)?
Answer: "Absolutely. Absolutely". He calls partnerships a "cornerstone" of their strategy to "increase the expansion of the market".
[00:04:58] If US prices go down, will prices increase elsewhere in the world to compensate?
Answer: He states that "price does go down everywhere in the world" as volume increases. However, as long as the company continues to innovate, they will "be able to get value for your innovation".
[00:05:34] How much of a game-changer can the new obesity pill be?
Answer: "A very big one". He says it's the first pill with efficacy "on par with the injectable," so patients won't have to choose between convenience and efficacy. He is also excited it will be the first GLP-1 product "made in US by Americans for Americans".
[00:06:52] What other areas are you looking at for potential impact?
Answer: Alzheimer's. He says it's an area with "huge unmet need" and that if their research proves to have an impact, "this is a gamecher," though he cautions it remains a "high-risk area".
[00:07:24] Where are you in the big restructuring plan?
Answer: It is "almost 95 95% complete" and was done at "record speed" to prevent the company from becoming "paralyzed". The restructuring was necessary to "readjusting our cost base" in the face of "competitive headwind" without sacrificing future investments.
[00:08:56] How difficult is it to have a very powerful chair just behind you?
Answer: He says his job is to set and execute the strategy. He states that the current and incoming board chairs are "all behind my appointment" and the new strategy, which gives him "a huge amount of excitement".
[00:10:27] What is the impact of the Trump administration and tariffs on European pharma?
Answer: He says that since Novo Nordisk exports more from the US than it imports, tariffs are "less of an issue" for them than for peers. He emphasizes they have "very big investments in Europe" as well and "simply try to be where we are operating".
[00:11:31] What is your priority now for Novo Nordisk?
Answer: First, "providing access to our medications" for those with unmet needs. Second, to "go deep into building our pipeline," both internally and through acquisitions, while running a good "sales to to cost ratio".
[00:12:19] What do you say to critics concerned about making anti-obesity drugs widely available?
Answer: He says if you talk to patients who have suffered their whole lives, you'd conclude "it's irresponsible for you not to make that available".
[00:12:44] What about making the drug accessible to people who don't need it?
Answer: He responds that their job is to "focus on those who need it," which is indicated by their drug labels and their entire approach.
Noteringen sluttede vist også lidt højere i USA. Så det kan da være, at vi er heldige i morgen.
Novo Nordisk strikes US Medicare price deal - https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-accepts-ozempic-wegovy-rybelsus-prices-us-medicare-negotiations-2025-11-05/
